Among the study procedures, BPD produced the best metabolic outcomes (BPD > GCP > AGB), indicating that FGF-19 may target mitochondria in adipose tissue during T2D remission [107]. The gene discussed is FGF19; the disease is type 2 diabetes mellitus.